Dr. Nitin Pal Kalia | Microbiology | Best Researcher Award
National Institute of Pharmaceutical Education and Research Hyderabad- India
Author Profile
🎓Early Academic Pursuits
Nitin Pal Kalia embarked on his academic journey with a focus on biotechnology and clinical microbiology. He completed his M.Sc. in Biotechnology with first-class honors from Guru Nanak Dev University, Amritsar, Punjab, India, in 2006. His passion for research led him to pursue a Ph.D. in the Clinical Microbiology Division at the Indian Institute of Integrative Medicine (IIIM), Jammu, under the guidance of Dr. Inshad Ali Khan. During his doctoral studies (2007-2014), Dr. Kalia made significant contributions to the field, including groundbreaking work on the NorA efflux pump inhibitor capsaicin and its impact on Staphylococcus aureus.
🧑🏫Professional Endeavors
Assistant Professor at NIPER-Hyderabad
Since February 2021, Nitin Pal Kalia has been serving as an Assistant Professor in the Department of Biological Sciences at the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. His office, Room No. 63, has become a hub for innovative research and academic excellence.
Ramalingaswami Fellow
From August 2019 to February 2021, Dr. Kalia held the prestigious Ramalingaswami Fellowship at CSIR-IIIM, Jammu, India. This fellowship allowed him to further his research in drug discovery and tuberculosis.
Research Fellow at NTU Singapore
Between October 2015 and August 2019, Dr. Kalia was a Research Fellow at the Lee Kong Chian School of Medicine, NTU Singapore. Here, he honed his skills in advanced research methodologies and contributed to significant scientific discoveries.
Visiting Fellow at NIAID-NIH
Dr. Kalia also spent time as a Visiting Fellow at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, USA, from May 2014 to July 2015. This experience enriched his research capabilities, particularly in the field of tuberculosis and mycobacteria.
🔬Contributions and Research Focus
Drug Discovery in Tuberculosis
Dr. Kalia’s research has been pivotal in the field of tuberculosis (TB), which remains a major global health challenge. He has focused on discovering new TB drugs and improving the clinical development process for these drugs. His work includes targeting terminal oxidases, specifically the respiratory cytochrome bc1 complex and cytochrome bd-type quinol oxidase, to combat drug-resistant Mycobacterium tuberculosis.
Targeting Cell Wall Synthesis at NIH
During his tenure at NIH, Dr. Kalia evaluated new chemical entities against Mycobacterium tuberculosis mutants. His work aimed to find compounds that target cell wall synthesis, a critical area in TB drug development.
Doctoral Research on Capsaicin
Dr. Kalia’s Ph.D. research revealed capsaicin as an effective inhibitor of the NorA efflux pump in Staphylococcus aureus. His findings demonstrated that capsaicin could significantly reduce the minimum inhibitory concentration of ciprofloxacin and enhance its efficacy, highlighting its potential in overcoming antibiotic resistance.
🏆Accolades and Recognition
Dr. Kalia’s contributions to biomedical research have been recognized through numerous awards and fellowships:
- Ramalingaswami Re-entry Fellowship (2017-2018): Awarded by the Department of Biotechnology (DBT), Government of India.
- BSL-3 Training: Attended training sessions on biosafety, bio-containment, risk assessment, and management at the National University of Singapore and NIH USA.
- IIIM-CSIR Award (2013): Recognized for significant contributions in Discovery Biology, particularly in tuberculosis research.
- Indian Council of Medical Research-Senior Research Fellowship: Awarded for his project on evaluating capsaicin and its analogues as multidrug efflux pump inhibitors.
🌍Impact and Influence
Dr. Kalia’s work has had a profound impact on the field of infectious diseases, particularly tuberculosis. His research has paved the way for new drug discoveries and therapeutic strategies. His dedication to teaching and mentoring students at NIPER-Hyderabad has inspired many young minds to pursue careers in biomedical research.
🚀Legacy and Future Contributions
As an Assistant Professor at NIPER-Hyderabad, Dr. Kalia continues to advance the frontiers of biomedical research. His ongoing projects aim to discover new TB drugs and improve existing treatments. Dr. Kalia’s legacy lies in his unwavering commitment to scientific excellence and his ability to inspire future generations of researchers.
Citations
A total of 1513 citations for his publications, demonstrating the impact and recognition of his research within the academic community.
- Citations 1513
- h-index 19
- i10-index 21
Notable Publications
- Title: Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase
- Authors: [Authors not provided]
- Journal: RSC Medicinal Chemistry
- Year: 2024
- Title: Cytochrome bd oxidase: an emerging anti-tubercular drug target
- Authors: [Authors not provided]
- Journal: RSC Medicinal Chemistry
- Year: 2024
- Title: GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876
- Authors: [Authors not provided]
- Journal: Microbiology Spectrum
- Year: 2023-12-12
- Title: Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection
- Authors: [Authors not provided]
- Journal: European Journal of Clinical Microbiology & Infectious Diseases
- Year: 2023-11
- Title: Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli
- Authors: [Authors not provided]
- Journal: Journal of Medical Microbiology
- Year: 2023-06-01.